Researchers from Foghorn Therapeutics Inc. recently presented preclinical data for FHD-609, a heterobifunctional degrader of BRD9 designed for the treatment of sarcoma. Synthesis and optimization of a series of first-generation compounds led to the identification of FHD-609 as a rapid, selective and highly potent BRD9 degrader, with high plasma stability and acceptable solubility.